What’s the current market cap for Veradermics stock?

Veradermics (MANE) has a market cap of $5.3bn as of June 27, 2026.

What is the P/E ratio for Veradermics stock?

The price to earnings (P/E) ratio for Veradermics (MANE) stock is 0 as of June 27, 2026.

Does Veradermics stock pay dividends?

No, Veradermics (MANE) stock does not pay dividends to its shareholders as of June 27, 2026.

When is the next Veradermics dividend payment date?

Veradermics (MANE) stock does not pay dividends to its shareholders.

What is the beta indicator for Veradermics?

Veradermics (MANE) does not currently have a Beta indicator.

Buy Veradermics stock | $MANE Share Price

13:30

15:10

16:45

18:25

20:00

About Veradermics

Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.

Ticker

$MANE

Sector

Health

Primary listing

NYSE

Employees

Headquarters

New Haven, United States

Website

www.veradermics.com

Veradermics Metrics

BasicAdvanced

$5.3bn

-$16.19

What the Analysts think about Veradermics

Analyst ratings (Buy, Hold, Sell) for Veradermics stock.

Bulls say / Bears say

Veradermics raised $256.3 million in its upsized IPO priced at $17 per share in February 2026, providing a strong cash position to fund ongoing Phase 3 trials. (Bloomberg‎)

Shares of MANE surged 122 percent in their NYSE trading debut, reflecting robust investor demand for its lead candidate VDPHL01. (Bloomberg‎)

In a late-stage Phase 2/3 “302” trial, males treated with VDPHL01 gained an average of 30–33 hairs per cm² over six months versus ~7 hairs per cm² for placebo, demonstrating both efficacy and a favorable safety profile. (STAT News‎)

Veradermics reported net losses of $21.8 million in Q4 2025 and $70.0 million for the full year 2025, highlighting significant cash burn ahead of any product revenue. (Business Wire‎)

Regulatory disclosures warn that the FDA may not accept the Section 505(b)(2) pathway for VDPHL01, risking delays or increased costs if a full New Drug Application is required. (Business Wire‎)

Off-label low-dose oral minoxidil treatments sold by telemedicine platforms like Hims & Hers and Ro pose a competitive challenge to VDPHL01’s market adoption, potentially undermining pricing power. (BioPharma Dive‎)

Data summarised monthly by Lightyear AI. Last updated on 15 Jun 2026.

Veradermics Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Veradermics Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.